Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Mercian Corporation is a Tokyo-based operating unit of Kirin, primarily engaged in the production and retail of wine and other alcoholic beverages. Chateau Mercian, produced and sold in Japan, is one of the most widely available brands of Japanese wine. Mercian Corporation also markets imported wine such as Casillero del Diablo, Frontera, and Sunrise brands in partnership with Concha y Toro, a leading Chilean wine producer.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Pharmaceuticals

Banyu Pharmaceutical Co. Ltd. produces and distributes pharmaceutical products. It researches, develops, manufactures, sells, and imports and exports ethical drugs in Japan. Banyu Pharmaceutical was founded in 1915 and is headquartered in Tokyo, Japan.

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Sanraku, Inc. is a private company headquartered in Japan that operates restaurants.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Huakang Supply Chain (Shandong) Co., Ltd., established on 2013-11-22, Business scope includes general items:Supply Chain Management Services;Refractory Sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Non-ferrous metal alloy sales;Petroleum product sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);refinery,Sales of special equipment for chemical production;Rubber Products Sales;Sales of high-purity elements and compounds;Sales of Surface Functional Materials;Sales of new organic active materials;Pigment sales;Sales of fire blocking materials;Sponge products sales;Sales of non-metallic minerals and products;Machinery sales;Sales of plastic products;Sales of building materials;Sales of building decoration materials;Sales of lightweight building materials;Metal Material Sales;Metal Ore Sales;Metal Products Sales;Coal and product sales;Cement products sales;Auto Parts Wholesale;wood sales;Wholesale of hardware products;Hardware retail;Electrical Equipment Sales;Instrument sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Conference and Exhibition Services;Domestic Freight Forwarding.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:mineral resources(non-coal mine)mining;road freight transport(Does not contain dangerous goods).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Part of Kitasato University, The Kitasato Institute is a company headquartered in Tokyo, Japan, that operates a research institution.

Shandong Zhongda Pharmaceutical Co., Ltd., established on 2003-09-02, Business scope includes pharmaceuticals,food,Healthy food,hygiene products,disinfectant(Does not contain dangerous goods),medical instruments,Production of masks,Sales;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval),Import and export agency;Value-added Telecom Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Whittemore Peterson Institute researches neuro-immune diseases including myalgic encephalomyelitis, fibromyalgia, and similar complex chronic diseases of the immune system and the brain. They provide scientific discovery and access to treatments, for patients with complex NIDs through grant support for institute-based clinical research studies and onsite medical practices.

Chisso Corp. engages in the manufacture and sale of chemical products. It offers liquid crystals, polyolefin composite fibers, coated fertilizers, and chemical fertilizers. The company was founded on January 12, 1906 and is headquartered in Tokyo, Japan.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

Manufactures chemicals